Tuberculosis future or investigational therapies: Difference between revisions
Jump to navigation
Jump to search
| Line 15: | Line 15: | ||
5) Role of immunomodulation | 5) Role of immunomodulation | ||
===New drugs involved in clinical trial for treatment of tuberculosis=== | |||
{| style="border: 0px; font-size: 90%; margin: 3px;" align=center | {| style="border: 0px; font-size: 90%; margin: 3px;" align=center | ||
Revision as of 14:50, 25 September 2014
|
Tuberculosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Tuberculosis future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Tuberculosis future or investigational therapies |
|
Tuberculosis future or investigational therapies in the news |
|
Risk calculators and risk factors for Tuberculosis future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]
Overview
Future investigations
In future therapies the following questions must be pondered on.
1) How can we shorten chemotherapy?
2) How can the interval between the therapy reduced ?
3) How can new drugs be developed ?
4) What is the best therapy for tuberculosis with HIV ?
5) Role of immunomodulation
New drugs involved in clinical trial for treatment of tuberculosis
| Drug | Phase | Class}} |
|---|---|---|
| Moxifloxacin | Phase III | Fluoroquinolone |
| Linezolid | Phase II | Oxazolidinone |
| AZD-5847 | Phase II | Oxazolidinone |
| Sutezolid | Phase II | Oxazolidinone |
| Clofazimine | Phase II | Riminophenazine |
| SQ-109 | Phase II | Ethylenediamine |
| PA-824 | Phase IIb | Nitroimidazole |
| Delamanid | Phase III | Nitroimidazole |
| Bedaquiline | Phase III | Diarylquinoline |
| Data provided by WHO[1] | ||